Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology

被引:14
作者
Bansal, Akriti [1 ]
Srinivasan, Radhika [1 ]
Rohilla, Manish [1 ]
Sundaram, Archana [1 ]
Rai, Bhavana [2 ]
Rajwanshi, Arvind [1 ]
Suri, Vanita [3 ]
Saha, Subhash C. [3 ]
Gupta, Nalini [1 ]
Gupta, Parikshaa [1 ]
Dey, Pranab [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res, Dept Radiotherapy & Oncol, Chandigarh, India
[3] Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh, India
关键词
High-grade serous carcinoma ovary; Ascitic fluid; Fine-needle aspiration; Ovarian carcinoma; Neoadjuvant chemotherapy; NACT; NEOADJUVANT CHEMOTHERAPY; CANCER; PAX8; EXPRESSION; WT1; TUBOOVARIAN; PERITONEAL; MARKER; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMA;
D O I
10.1093/ajcp/aqaa028
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: High-grade serous carcinoma (HGSC) is the most common ovarian malignancy. The role of cytopathology in obtaining tissue diagnosis before institution of neoadjuvant chemotherapy (NACT) was evaluated. Methods: All histopathology-proven HGSC specimens between 2015 and 2018 with prior cytopathologic diagnosis by ascitic fluid evaluation or fine-needle aspiration (FNA) of ovarian mass were reviewed with cell block immunocytochemistry for CK7, CK20, PAX8, WT1, and p53. Results: Of 288 cases of HGSC, pre-NACT cytology diagnosis was established in 32% (93/288), with specific HGSC diagnoses made on ascitic fluid in 88% (82/93) and by ovarian mass FNA in 12% ( 11/93). The ascitic fluid showed moderatelhigh cellularity with papillary clusters in 76% (71/93) cases. Cell block immunocytochemistry showed tunior cells positive for CK7, PAX8, and WT1. p53 showed mutant or null-type positivity in 65% (33/51) and 33% (17/51) of cases, respectively, with 100% concordance with subsequent histopathologv specimens Poor/intermediate response to chemotherapy was shown in 75% of cases. Conclusions: Combined assessment of cytomorphology, cell block histomorphology, and ancillary immunohistochemical testing, including PAX8, WT1, and p53, allows for specific pre-NACT diagnoses of HGSC in ascitic fluid and ovarian FNA cytology. This practice allows for initiation of chemotherapy and diminution of disease burden prior to definitive surgical therapy.
引用
收藏
页码:103 / 114
页数:12
相关论文
共 29 条
[1]   WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma [J].
Al-Hussaini, M ;
Stockman, A ;
Foster, H ;
McCluggage, WG .
HISTOPATHOLOGY, 2004, 44 (02) :109-115
[2]   Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma [J].
Boehm, Steffen ;
Faruqi, Asma ;
Said, Ian ;
Lockley, Michelle ;
Brockbank, Elly ;
Jeyarajah, Arjun ;
Fitzpatrick, Amanda ;
Ennis, Darren ;
Dowe, Thomas ;
Santos, Jennifer L. ;
Cook, Linda S. ;
Tinker, Anna V. ;
Le, Nhu D. ;
Gilks, C. Blake ;
Singh, Naveena .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) :2457-U73
[3]   Emerging roles for PAX8 in ovarian cancer and endosalpingeal development [J].
Bowen, Nathan J. ;
Logani, Sanjay ;
Dickerson, Erin B. ;
Kapa, Laura B. ;
Akhtar, Mariam ;
Benigno, Benedict B. ;
McDonald, John F. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :331-337
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy [J].
Casey, Laura ;
Kobel, Martin ;
Ganesan, Raji ;
Tam, Simone ;
Prasad, Rajeev ;
Bohm, Steffen ;
Lockley, Michelle ;
Jeyarajah, Arjun J. ;
Brockbank, Eleanor ;
Faruqi, Asma ;
Gilks, C. Blake ;
Singh, Naveena .
HISTOPATHOLOGY, 2017, 71 (05) :736-742
[6]   Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data [J].
Cohen, Paul A. ;
Powell, Aime ;
Bohm, Steffen ;
Gilks, C. Blake ;
Stewart, Colin J. R. ;
Meniawy, Tarek M. ;
Bulsara, Max ;
Avril, Stefanie ;
Brockbank, Eleanor C. ;
Bosse, Tjalling ;
de Azevedo Focchi, Gustavo Rubino ;
Ganesan, Raji ;
Glasspool, Rosalind M. ;
Howitt, Brooke E. ;
Kim, Hyun-Soo ;
Lee, Jung-Yun ;
Le, Nhu D. ;
Lockley, Michelle ;
Manchanda, Ranjit ;
Mandalia, Trupti ;
McCluggage, W. Glenn ;
McNeish, Iain ;
Midha, Divya ;
Srinivasan, Radhika ;
Tan, Yun Yi ;
van der Griend, Rachael ;
Yunokawa, Mayu ;
Zannoni, Gian F. ;
Singh, Naveena .
GYNECOLOGIC ONCOLOGY, 2019, 154 (02) :441-448
[7]   Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC) [J].
Ditzel, Helena M. ;
Strickland, Kyle C. ;
Meserve, Emily E. ;
Stover, Elizabeth ;
Konstantinopoulos, Panagiotis A. ;
Matulonis, Ursula A. ;
Muto, Michael G. ;
Liu, Joyce F. ;
Feltmate, Colleen ;
Horowitz, Neil ;
Berkowitz, Ross S. ;
Gupta, Mamta ;
Hecht, Jonathan L. ;
Lin, Douglas I. ;
Jochumsen, Kirsten M. ;
Welch, William R. ;
Hirsch, Michelle S. ;
Quade, Bradley J. ;
Lee, Kenneth R. ;
Crum, Christopher P. ;
Mutter, George L. ;
Nucci, Marisa R. ;
Howitt, Brooke E. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (03) :230-240
[8]   Mannose Binding Lectin Is Required for Alphavirus-Induced Arthritis/Myositis [J].
Gunn, Bronwyn M. ;
Morrison, Thomas E. ;
Whitmore, Alan C. ;
Blevins, Lance K. ;
Hueston, Linda ;
Fraser, Robert J. ;
Herrero, Lara J. ;
Ramirez, Ruben ;
Smith, Paul N. ;
Mahalingam, Suresh ;
Heise, Mark T. .
PLOS PATHOGENS, 2012, 8 (03)
[9]  
Hwang H, 2004, APPL IMMUNOHISTO M M, V12, P122
[10]  
Ko EC, 2001, AM J CLIN PATHOL, V116, P709